The week of July 13, 2026, US Defense Secretary Pete Hegseth ordered annual testosterone-deficiency screening for active-duty and reserve service members aged 30 and older, framing it as a move to bolster military "readiness and performance." Within days, the directive drew sharp pushback: five of six men's-health experts contacted by Reuters said they were puzzled by the announcement and worried it could lead to unnecessary — or even harmful — treatment, according to coverage carried by Reuters, The Straits Times, Newsweek and Firstpost.

Why It Matters

The military is one of the largest single healthcare systems in the US, and a blanket testosterone-screening mandate for its 30-plus population could shift cultural and clinical norms far beyond the barracks — feeding directly into the booming TRT telehealth market. But the near-unanimous expert skepticism underscores the industry's core tension: destigmatized access to men's hormone therapy versus evidence-based prescribing. How the Pentagon handles "abnormal" results will be a real-world stress test of where that line sits.

The clinical objection is that routine population-wide testosterone screening of otherwise healthy men isn't supported by major urology or endocrinology guidelines, which reserve testing for men with actual symptoms of hypogonadism. Physicians warned that flagging "low" numbers in asymptomatic troops could push service members toward testosterone replacement therapy (TRT) they don't need — raising risks including infertility, and inviting inappropriate anabolic use. The Pentagon has not published detailed guidance on how abnormal results will be evaluated, or whether screening will apply equally to men and women. Hegseth said testing would come with advice to help members make treatment decisions, and that any treatment would be voluntary.

The order fits a pattern of contested health-policy moves from the current administration's defense and health leadership — the same reporting noted Hegseth's earlier reversal of the military flu-vaccine mandate (walked back after an outbreak) and HHS's removal of 17 members from a vaccine advisory panel. Critics see the testosterone mandate as part of a broader "masculinity and performance" framing of military fitness rather than an evidence-driven screening program.

For the sexual-health industry, the directive is a curious macro signal. It arrives as the FDA separately opens pathways toward approved testosterone indications for low libido and weighs descheduling testosterone, and as telehealth players (Hims, LifeMD's XYOSTED deal, Marius's Kyzatrex) race to expand TRT access. A government-mandated screening cohort of hundreds of thousands of men over 30 could normalize testosterone testing broadly — or, if it produces a wave of questionable prescriptions, become a cautionary tale about over-medicalizing "low-T."

Sources

Update — 2026-07-19

{Initial entry — story first created.}

Update — 2026-09-09

The guidance finally appeared — and vanished within 24 hours. On September 2, 2026, roughly seven weeks after Hegseth's July announcement, the Pentagon posted the clinical document implementing the policy: "Clinical Guidance for Health and Human Performance Optimization." By September 3 the memo and an accompanying statement from spokesperson Sean Parnell had both been pulled, with "Page Not Found" appearing on both the Pentagon and Defense Health Agency links. Reuters broke the withdrawal.

In a statement to Ars Technica, the Pentagon said the September 2 draft "has been temporarily rescinded to allow for updates," adding that interim guidance remains in effect and "the final clinical guidance will be issued shortly." The Department "remains committed to addressing hormone deficiencies, protecting the long-term health of its Service members, and enabling peak operational performance." It declined to say what was being updated or why the revision was needed within a day of publication.

The now-withdrawn document filled in details the July announcement left blank, and they are directly relevant to this beat. Per Reuters via Military Times, it laid out separate screening paths for men and women during annual health assessments, effective immediately. Men 30 and older would be screened via questionnaire, which could trigger a blood test for testosterone and, if indicated, testosterone hormone therapy. Women would also be screened by questionnaire, potentially leading to treatment for hormonal imbalance conditions — with testosterone used in women only for diagnoses where there is evidence of efficacy, explicitly naming Hypoactive Sexual Desire Disorder, "characterized by a distressing level of low sexual interest." That is the first time this policy has been formally tied to a sexual health indication, and it puts the military in the position of screening service members for HSDD at scale.

Expert opposition has not softened since July. Ars Technica notes neither the Endocrine Society nor the American Urological Association supports routine low-testosterone screening. Dr. Jason Goldman, immediate past president of the American College of Physicians, told Reuters: "Taking testosterone is not going to make you more manly, more strong, or a more robust individual. That's just not how it works. It's just bad policy all around." Bradley Anawalt, chief of medicine at the University of Washington Medical Center, told Ars: "We're turning the clock back on rational health care. I'm worried about the ethics. I'm worried about the health consequences. I'm worried about unnecessary evaluations, incorrect assessments, and incorrect diagnoses that lead to inappropriate prescriptions of testosterone." Ars lists the risks of conventional TRT as decreased fertility, elevated red blood cell counts, acne, increased prostate size and sleep apnea, with higher doses associated with cardiovascular disease and prostate cancer.

For the TRT telehealth sector, the same-day retraction is a signal worth reading carefully. The prospect of a mandatory screening cohort numbering in the hundreds of thousands has been treated as a normalization tailwind for the category — but a policy that cannot survive 24 hours of public scrutiny is a shaky foundation to build a demand thesis on, and a clumsy rollout that produces a wave of questionable prescriptions would hand critics of direct-to-consumer testosterone exactly the case study they've been waiting for.

New Sources